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FOXP3 INTERACTS WITH AND REGULATES HIF-1a-VEGF SIGNALING IN
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Purpose: To investigate the prognostic role and molecular mechanism of
Foxp3 expression in human bladder cancer.
Materials and Methods: Using quantitative RT-PCR and western blotting
analysis, T24 parental and metastatic sublines were investigated for Foxp3,
glucose transporter ( GLUT), and VEGF expression. The interaction be-
tween Foxp3 and HIF-1a were explored using immunoprecipitation, and
confocal microscopic studies. Foxp3 expression was examined for the
prognostic values in bladder urothelial carcinoma using Foxp3 and CD8
immunostaining. Using data mining, the association between Foxp3, VEGF,
and GLUT member expression were explored.
Results: Foxp3 expression is associated with the metastatic potential
among three human bladder cancer T24 sublines, as well as higher
expression of glucose transporter (GLUT) members and vascular endo-
thelial growth factor (VEGF) expression and more aerobic glycolysis. Via
immunoprecipitation, and confocal microscopic studies, Foxp3 protein can
bind with and maintain HIF-1a expression post-translationally. Knocking-
down of Foxp3 expression blocks in vivo tumor growth in mice and pro-
longs mice's survival, which is associated with von Willebrand factor
expression. Forty-three of 145 (22.8 %) bladder tumors exhibit Foxp3
expression. Foxp3 expression is an independent predictor for disease
progression in superﬁcial bladder cancer patients (p¼0.032), associated
with less number of intratumoral CD8+ lymphocyte. The metaanalysis
from 2 published datasets showed Foxp3 expression is associated with
GLUT-4,-9, and VEGF-A, B-, D expression
Conclusion: Foxp3 expression in bladder tumor cells can bind with and
regulate HIF-1a signaling post-translationally, contributing to be an in-
dependent prognostic marker for progression in bladder cancer.
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Purpose: Renal cell carcinoma (RCC) accounts for about 3% of all cancer-
related mortalities worldwide and the risk factors for the development of
RCC have not yet been fully elucidated. Mounting proteomic evidence
suggests that inﬂammatory process plays a role in RCC etiology, and
interleukin-10 (IL-10) is an important immunosuppressive cytokine.
However, little is known about the contribution of IL-10 genotypes to RCC.
The study aimed at evaluating the contribution of IL-10 promoter A-1082G
(rs1800896), T-819C (rs3021097), A-592C (rs1800872) genetic poly-
morphisms to the risk of RCC in Taiwan.
Materials and Methods: Associations of the three IL-10 polymorphic ge-
notypeswith the risk of RCCwere examined among 92 RCC patients and580
age- and gender-matched cancer-free controls by polymerase chain reac-
tion-restriction fragment length polymorphism (PCR-RFLP) methodology.* These authors contribute equally to this workResults: The pilot results showed that the percentages of TT and TC for IL-
10 T-819C genotypes were signiﬁcantly higher in the RCC patient group
than those in the healthy control group. The CC genotype carriers were of
lower risk for RCC (odds ratio¼0.45, 95% conﬁdence interval¼0.23-0.72,
p¼0.0033). There is no difference in the distribution of A-1082G or A-592C
genotype between the RCC and control groups.
Conclusion: In summary, the CC genotype of IL-10 T-819C genotype may
have a protective effect on RCC risk in Taiwan. Further investigation with
larger sample size in addition to genotype-phenotype correlation and
intracellular mechanisms are our future work.
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Purpose: To follow up the oncologic outcomes of patients who underwent
nephroureterectomy with endoscopic bladder cuff excision (Pluck
method) under the diagnosis of upper tract urothelial carcinoma.
Materials and Methods: Between May 2004 to November 2015, 147 pa-
tients with upper urinary tract urothelial carcinoma received laparoscopic
radical nephroureterectomy with endoscopic bladder cuff excision at our
institution. The medical records were reviewed retrospectively for clinical
and pathological facts. Statistical analyses were made for factors theoret-
ically related to predicting oncological outcomes.
Results: The median follow-up time was 26 months. 27 patients (22.9%)
developed bladder recurrence as local recurrence found in 4 cases (3.4%).Me-
tastaseswere found in 17 patients (14.4%).Male genderwas statistical signiﬁ-
cantly related to bladder recurrence inmultivariate analysis (OR: 2.2; 95%C.I.:
1.02 e 4.78; p: 0.045). Tumor size was the only predictive factor for local
recurrence(mean:5.0cmversus3.2cm;OR:1.29;95%C.I.:1.07e3.43;p:0.029).
Tumor stagingwas related to subsequentmetastasis (OR: 2.08; 95%C.I.: 1.21e
3.56; p: 0.008) and overall survival (OR: 1.84; 95%C.I.: 1.06e 3.22; p: 0.031).
Conclusion: In patients with upper tract urothelial carcinoma received
laparoscopic nephroureterectomy with pluck method bladder cuff exci-
sion, the prognostic factor of bladder recurrence is male gender as larger
tumor indicating higher risk of locoregional recurrence. Advanced staging
carries higher possibility of subsequent metastasis and mortality.
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NEOADJVANT HORMONE THERAPY FOR LOCALIZED PROSTATE CANCER:
INITIAL EXPERIENCES IN INTERMITTENT-AND HIGH-RISK PATIENTS IN
THE ROBOTIC SURGERY ERA
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Purpose: Current guidelines suggest that patients with intermediate- or
high-risk prostate cancer (CaP) could be offered neoadjuvant hormone
therapy (NHT) before they receive deﬁnitive radiation therapy. However,
no powerful evidences showed NHT has prognostic beneﬁts to patients
receiving robotic-assisted laparoscopic radical prostatectomy (RaLRP) yet.
This study was to compare the results of RaLRP in patients who did and did
not receive NHT, especially focus on intermediate- and high-risk patients.
Materials and Methods: Patients received NHT prior to RaLRP by a single
surgeon were identiﬁed from the VGHTC Prostate Cancer Database. Con-
trol group was picked out via computerized 1:1 ratio matching with the
following criteria: (1) prostate speciﬁc antigen (PSA) level at diagnosis (2)
initial Gleason score (3) clinical stage (4) Age. NHT regimens include
combination of Luteinising hormone-releasing hormone (LHRH) agonist
with anti-androgens and individual use of either LHRH agonist or anti-
androgens. General characters of patients, peri-operative parameters,
functional and oncologic outcome were prospectively recorded.
Abstracts / Urological Science 27 (2016) S36eS52S46Results: Total 48 patients with D'Amico intermediate- and high-risk CaP
were analyzed. The mean patient age, BMI, preoperative PSA, and Gleason
score at biopsy appears equivalent but there're signiﬁcant statistic higher
percentage of cT2c in control group and a trend of higher percentage of
cT3b in NHT group. Shorter operative time (153.5 minutes v.s. 113.3 mi-
nutes, p¼0.0002) and lesser amount of blood loss (147.08ml v.s. 93.75ml,
p¼0.131) were found in NHT group. The average period of biochemical
recurrence (BCR) was similar (5.33 months v.s. 6.54 months, p¼0.523) but
the overall BCR rate was signiﬁcantly lower in NHT group (87.5% v.s. 54.2%,
p¼0.026). In sub-group analysis, BCR rate was signiﬁcant lower in NHT
group if preoperative PSA level were between 10 to 20 ng/ml (66.67% v.s.
0%, p¼0.035) and >50 ng/ml (100% v.s. 55.56%, p¼0.018) while BCR rate
was 81.82% v.s. 80% (p¼0.916) in PSA 20-50 ng/ml. However, average
follow-up period was signiﬁcantly insufﬁcient in NHT group (49.46
months v.s. 20.29 months, p<0.001) although BCR usually happened in the
postoperative ﬁrst year in our study.
Conclusion: Neoadjuvant NHT followed by RaLRP seems to provide some
potential beneﬁts in shorter operative time, lesser amount of blood loss,
and lower rate of BCR during postoperative two years in patients with
intermediate- or high-risk localized CaP.
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Purpose: Although partial cystectomy is not the gold standard treatment
for muscle-invasive bladder cancer, a solitary lesion in a suitable location is
amenable to segmental resection with adequate margins. On the other
hand, when advanced gynaecological or colorectal malignancy involves
the urinary bladder, partial cystectomy has its role in bladder preservation
for better quality of life. Thus we review our experience of treating pelvic
malignancy with partial cystectomy at our institution.
Materials and Methods: From 1991 to 2010, a total of 45 patients un-
derwent partial cystectomy as en bloc resection for urological and non-
urological pelvic malignancies. Fifteen of themwere pT1-3 bladder cancer,
mostly urothelial carcinoma. The other 30 patients had urinary bladder
invasion from colorectal or gynaecological cancers. We retrospectively
reviewed these cases to evaluate the oncologic control perioperative
morbidities, and quality of life after partial cystectomy.
Results: Five of 15 patients were lost to follow up, thus the median fol-
lowupwas 48.4months (50%male, mean age: 66.2). 5-year recurrence free
rate was 50% (5/10), median time to recurrence was ten months. Mortality
rate was 20% (2/10). In mortality cases, one patient is diagnosed with bone
metastases initially and another patient is later diagnosed with pT4N2Mx
after he received radical cystectomy.16 of 29 patients were diagnosed with
bladder invasion after formal pathological report, only one case had uri-
nary bladder recurrence in 7 months. One patient expired in 3 months due
to pneumonia, 14 patients were recurrence free in urinary bladder at least
1 year, mean recurrence free time is 5.54 years.
Conclusion: From our experience, partial cystectomy for bladder cancer
control is still controversial. Further prospective or large scale study is
needed. However, en bloc resection for non-urological pelvic malignancy
in bladder invasion is feasible for tumor control.
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OUTCOME OF LAPAROSCOPIC RADICAL PROSTATECTOMY WITH
INTENDED WIDE RESECTION IN PROSTATE CANCER PATIENTS WITH A
PREOPERATIVE SERUM PSA LEVEL > 50 NG/ML: A SINGLE SURGEON
EXPERIENCE
Yen-Hsi Lee 1, Henry Y. Lin 1, Chung-Hsien Chen 1, Yu-Chi Chen 1, Victor C.
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of Medicine for International Students, I-Shou University, Kaohsiung, TaiwanPurpose: Toassess theoutcomeofprostatecancerpatientswithpreoperative
prostate-speciﬁc antigen (PSA) levels over than 50 ng/ml who were treated
with laparoscopic radical prostatectomywith intended wide resection.
Materials and Methods: Total twelve patients from Jan. 2007 to Dec. 2015
with prostate cancer who underwent laparoscopic radical prostatectomy
with intended wide resection had an initial PSA level over than 50 ng/ml
were included in this study. Overall survival, cancer-speciﬁc survival and,
peri-operative and post-operative parameters and pathologic features, per-
centage of neoadjuvant hormone therapy, adjuvant therapy were analyzed.
Results: ThemeanserumPSA levelwas89.4 (50.6-191.0)ng/ml. Fourpatients
(33%) received neoadjuvant hormone therapy. Two patients were classiﬁed
as stage pT2, three as pT3a, four as pT3b and three as pT4. Three patients had
pelvis lymph nodemetastasis. Six patients (50%) received adjuvant hormone
therapy. Three patients had PSA failure and two received salvage radio-
therapy. Overall survival and cancer-speciﬁc survival were 100% and 100%,
respectively, during mean follow up of 3.9 years. Continence rate was 91.7%
and average recovery time was 62 (7-287) days. Potency rate was 8.3%.
Conclusion: The study showed a relatively feasible outcome for clinically
non-metastatic but locally advanced prostate cancer with PSA levels over
than 50 ng/ml treated by laparoscopic radical prostatectomy with inten-
ded wide resection.
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Purpose: Angiomyolipoma (AML) is a benign neoplasm composed of
varying admixtures of blood vessels, smooth muscle cells, and adipose
tissue. However, it often leads to spontaneous hemorrhagic, pain or he-
maturia if large size. Invasive interventions including embolization,
nephron-sparing surgery, or even nephrectomy were suggested for larger
tumor. Due to increase risk of bleeding in larger tumor during operation,
preoperation transcatheter arterial embolization (TAE) in larger tumor
maybe can make the surgery more smoothly and decrease intra-operation
blood loss. Hence, we are here to share our hospital’s clinical experience.
Materials and Methods: From March 2012 to November 2015, 13 cases of
large AML (tumor size S7cm) underwent the nephron-sparing surgery in
Chi Mei Medical Center. Preoperation transcatheter arterial embolization
wasperformed in 6 cases (TAEgroup) and theother 7 cases are not (Non-TAE
group). Patient demographics, tumor characteristics, intraoperative, and
postoperativedata including tumor size,warm ischemia time, andestimated
blood loss (EBL) were analyzed and compared between these two group.
Results: From March 2012 to September 2015, there were 5 male and 8
female patients met the inclusion criteria. The mean age was 46-year-old.
Most of them have the chief complaint of ﬂank pain (61.5%), because of
tumormass effect or rupture. The average tumor sizewas 11.7cm (7-22) and
the average nephrometry score was 8. In the TAE group, mean warm
ischemia time (WIT) was 5 min 02 sec and Non-TAE group was 11 min 32
sec. Mean blood loss was 1650ml (300-4000) in TAE group and 1900ml
(50~7200) inNon-TAE group. Themeanpost operation length of l staywas 5
days in TAE group and 6.4 days in Non-TAE group. In Non-TAE group, there
were 3 patient (43%) showed residual tumor during post op follow up im-
aging study and only 1 patient (16%) showed residual tumor in TAE group.
Conclusion: In large AML case, TAE before partial nephrectomy had
shorterWIT, decrease intra-operation blood loss, shorter length of stay and
fewer residual tumor than those did not performed TAE.
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